RBC Capital raised the firm’s price target on Leidos (LDOS) to $230 from $210 and keeps an Outperform rating on the shares. The company’s earnings topped estimates, driven by continued strength in Health & Civil margins, the analyst tells investors in a research note. RBC adds that Leidos’s 1.3x book-to-bill and $69B near-term pipeline is robust, though the ongoing shutdown contributed to a more conservative 2025 guidance raise.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LDOS:
- Leidos price target raised to $216 from $209 at UBS
- Leidos Holdings Inc. Reports Robust Q3 Earnings
- Leidos Holdings Inc. Reports Strong Earnings Amid Challenges
- Leidos price target raised to $220 from $200 at Truist
- Leidos Holdings: Hold Rating Amid Strong Q3 Results and Government-Related Challenges